dual anti-HER2/anti-PD-L1 CAR T-cell therapy (Sichuan University)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug Namedual anti-HER2/anti-PD-L1 CAR T-cell therapy (Sichuan University)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsProgrammed death-ligand 1 modulators
TargetsProgrammed death-ligand 1Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSichuan University
China Registration ClassN/A

Develop Information

Active CompaniesSichuan University
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A